Cardiff and Vale sets June 2027 date for costed cancer plan after audit
Cardiff and Vale University Health Board has set June 2027 as the completion date for a costed cancer improvement plan in its published response to an audit calling for urgent action. The response appears in an Audit Wales report published on 2 September 2026, which found that existing plans lacked the detail needed to support lasting improvement.
The board said its timetable would allow it to read and align local plans with a national cancer strategy it expected in February 2027. That expected release date is the board's explanation in the report, rather than a separately confirmed national timetable. Its proposed plan would cover demand, capacity, staffing and infrastructure, and go to the board for approval.
What the plan needs to show
Auditors recommended a plan costed over at least three to five years, with resources, measurable milestones and arrangements to track delivery. They found that the board's cancer strategy for 2023-28 set high-level priorities, but did not provide specific actions or clear accountability. The annual plan for 2026-27 was not enough on its own to explain how services would meet rising demand and treatment costs.
The report also acknowledged work already happening. Extra clinics, targeted recruitment and changes to how patients move through services were helping teams manage immediate pressures. Overall performance had not deteriorated despite substantial growth in demand. The concern was whether those measures could produce sustained improvement, with clear milestones and outcomes against which progress could be judged.
The published response dates
The management response also records December 2027 completion dates for appointing a cancer clinical lead and re-establishing the Cancer Delivery Board. Auditors had described the appointment as a priority and called for the delivery board to be restored urgently. In its response, the health board said recruitment was already under way and an advert was live. It planned to restore the delivery board alongside the appointment.
Those are the dates and explanations in the published response, not confirmation of the latest recruitment or governance position. They do not establish that an appointment could not happen sooner. The audit identified clear executive and operational leadership already in place; its criticism concerned dedicated clinical leadership and cancer-specific oversight.
What happens next
The costed plan would provide a way to judge the resources promised, the improvements expected and who is responsible for delivering them. The published timetable offers checkpoints for that scrutiny, rather than evidence that a future deadline has already been missed. This was an audit of improvement arrangements: its scope excluded the quality of clinical services, clinical governance and patient experience.